Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT07794761
Recruiting Phase 3

A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)

NCT07794761 · tracked via the Priya Life Science Japan tracker
Sponsor
Pfizer
Phase
Phase 3
Started
2026-10-02
Last updated
2026-10-15

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

Berobenatide →Placebo

Berobenatide: Solution for injection

Placebo: Solution for injection

Study summary

The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition where a person has too much body fat, which can harm their health and increase the risk of other medical problems. Some people in this study may also have type 2 diabetes, a condition in which the body does not use insulin properly, causing blood sugar levels to become too high.

This study is seeking participants in Japan who:

* Have obesity disease.
* May have type 2 diabetes.
* Meet the study-specific age, weight and health requirements.

About 180 adults will take part in this study. Participants will be randomly assigned to receive either berobenatide or a placebo. A placebo looks like the study medicine but does not contain any active medicine.

Berobenatide or placebo will be given as an injection under the skin of the abdomen (belly area). The study will compare the experiences of people receiving berobenatide with those receiving placebo to determine whether berobenatide can help people lose weight. The study will also assess the safety of berobenatide and its effects on body weight and other health measures.

People will take part in this study for about 22 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged ≥18 years. * BMI of: ≥27.0 kg/m2 to \<35.0 kg/m2 with ≥2 obesity-related health disorders or BMI of ≥35.0 kg/m2 with ≥1 obesity-related health disorder. The participant must have at least one of either hypertension, dyslipidemia or glucose intolerance (T2D and impaired glucose tolerance etc.) as an obesity-related health disorder. Exclusion Criteria: * Have a self-reported body weight change greater than 5% within 90 days prior to Screening. * Diagnosis of type 1 diabetes or any other form of diabetes other than T2D. * History of acute or chronic pancreatitis. * Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).

Primary outcome measure(s)

  • Percent change from baseline in body weight — Baseline, Week 72

Trial sites (34)

FacilityCityRegionStatus
Tokuyama Clinic Chiba Chiba Not Yet Recruiting
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism Matsuyama Ehime Not Yet Recruiting
Matsuyama Shimin Hospital Matsuyama Ehime Not Yet Recruiting
Tenjin Sogo Clinic Fukuoka Fukuoka Not Yet Recruiting
Medical Corporation BOOCS BOOCS CLINIC FUKUOKA Fukuoka Fukuoka Not Yet Recruiting
Oishi Clinic Kasuya-gun Fukuoka Recruiting
Manda Memorial Hospital Sapporo Hokkaido Recruiting
Yamasaki Family Clinic Amagasaki Hyōgo Not Yet Recruiting
Minami Akatsuka Clinic Mito Ibaraki Not Yet Recruiting
Nishiyamado Keiwa Hospital Naka Ibaraki Not Yet Recruiting
Olive Takamatsu Medical Clinic Takamatsu Kagawa-ken Not Yet Recruiting
Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic Yokohama Kanagawa Not Yet Recruiting
Yokoi Clinic Minoh Osaka Not Yet Recruiting
Kanemura Clinic Osaka-shi Ikuno-ku Osaka Not Yet Recruiting
Medical Corporation Heishinkai OCROM Clinic Suita Osaka Recruiting
MI Clinic, Medical Corporation Jinsenkai Toyonaka-shi Osaka Recruiting
Soka Sugiura Internal medicine Clinic Soka-shi Saitama Not Yet Recruiting
Doujin Memorial Foundation Meiwa Hospital Chiyoda-ku Tokyo Recruiting
AIC Yaesu Clinic Chuo-ku Tokyo Recruiting
Aic Yaesu Clinic Chuo-ku Tokyo Not Yet Recruiting
Tokyo Center Clinic Chuo-ku Tokyo Recruiting
Tokyo-Eki Center-building Clinic Chuo-ku Tokyo Not Yet Recruiting
Fukuwa Clinic Chuo-ku Tokyo Not Yet Recruiting
Tokyo Asbo Clinic Chuo-ku Tokyo Recruiting
Medical Corp. Seikoukai New Medical Research System Clinic Hachioji-shi Tokyo Recruiting
Hachioji Clinic Shincho Hachioji-shi Tokyo Recruiting
Keikokai Medical Corporation P-one Clinic Hachiōji Tokyo Not Yet Recruiting
Patient First Clinic Ginza-Shimbashi Minato-ku Tokyo Not Yet Recruiting
Shimamura Memorial Hospital Nerima-ku Tokyo Recruiting
Medical Corporation Heishinkai ToCROM Clinic Shinjuku-ku Tokyo Recruiting
Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical Corporation Shinjuku-ku Tokyo Recruiting
Higashi-Shinjuku Clinic, Keikokai Medical Corp. Shinjuku-ku Tokyo Recruiting
Ikebukuro Metropolitan Clinic Toshima-ku Tokyo Recruiting
Nihonbashi Sakura Clinic Tokyo Japan Recruiting

More Pfizer trials in Japan

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer Recruiting
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer Recruiting
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer Active, not recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata Recruiting
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use. Active, not recruiting

Other trials for the same condition

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes Starting soon
Cities for Better Health Childhood Obesity Prevention Initiative Enrolling by invitation
Study on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency. Recruiting
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes Starting soon
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07794761 on ClinicalTrials.gov ↗ ← All trials in Japan